Singapore, Nov. 16 -- Singapore-based Specialised Therapeutics has announced that the Thailand Food and Drug Administration has approved YONDELIS(R) (trabectedin) on for the treatment of adult patients with advanced soft tissue sarcoma (STS).

YONDELIS is an established antineoplastic agent originally derived from the sea squirt (Ecteinascidia turbinata). It exerts the anti-tumour effect by binding to the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from multiplying.

STS is a rare and complex disease. In Thailand, the age-standardised incidence rate of STS is 2.14 per 100,000 person-years, which is relatively low compared to Western nations. The most frequently reported histological subtypes among Thai patie...